Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Aquestive Therapeutics, Inc. Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study Today 8:00 EDT From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET July 23, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism June 27, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film June 25, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024 June 18, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities June 03, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference May 28, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference May 09, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update May 07, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film April 29, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET April 25, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology April 12, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive April 01, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST EBS GMDA Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock March 25, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock March 19, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics Announces Proposed Public Offering of Common Stock March 19, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting March 14, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update March 05, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET February 21, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting February 15, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference January 30, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film December 05, 2023 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting November 10, 2023 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update November 06, 2023 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics Completes $45 Million Debt Refinancing November 02, 2023 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8:00 a.m. ET October 31, 2023 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics Provides Business Update October 09, 2023 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm™ (epinephrine) Sublingual Film September 20, 2023 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics Receives FDA Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film in Pediatric Patients and Assignment of Prescription Drug User Fee Act (PDUFA) Date September 11, 2023 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences August 23, 2023 From Aquestive Therapeutics, Inc. Via GlobeNewswire Tickers AQST Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.